title: Potentials of cell kinetics in the management of patients with ovarian cancers.
abstract: The relevance of 3H-thymidine labeling index (3H-dt LI) on clinical outcome was evaluated on 85 patients with advanced ovarian cancers treated with carboplatin or cisplatin alone (39 cases) or cisplatin in association with doxorubicin and/or cyclophosphamide (46 cases). 3H-dT LI of the primary tumour was significantly related to the 3-year probability of survival in patients treated by monochemotherapy (low LI, 63%; high LI, 21%; P = 0.013) but not in those treated with polychemotherapy. Analysis of the relation between cell kinetics and clinical outcome as a function of treatment showed that in patients with rapidly proliferating tumours the 3-year survival was significantly higher following polychemotherapy than monochemotherapy (51 vs. 21%; P = 0.04). In patients with slowly proliferating tumours no significant difference in survival was observed following the two types of treatment for the overall series, whereas in patients not achieving a complete response survival was significantly higher following monochemotherapy than polychemotherapy (61 vs. 9%; P = 0.008).
authors.affiliation: Oncologia Sperimentale, Istituto Nazionale Tumori, Milan, Italy.
authors.forename: R
authors.initials: R
authors.lastname: Silvestrini
authors.forename: M G
authors.initials: MG
authors.lastname: Daidone
authors.forename: B
authors.initials: B
authors.lastname: Valentinis
authors.forename: C
authors.initials: C
authors.lastname: Ferraris
authors.forename: E
authors.initials: E
authors.lastname: Di Re
authors.forename: F
authors.initials: F
authors.lastname: Raspagliesi
authors.forename: F
authors.initials: F
authors.lastname: Landoni
authors.forename: G
authors.initials: G
authors.lastname: Scarfone
authors.forename: G
authors.initials: G
authors.lastname: Bolis
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000627:therapeutic use; D002455:Cell Division; D002945:Cisplatin / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology*
chemical_list: D016190:Carboplatin; D002945:Cisplatin